OptiNose

OptiNose develops nasal drug delivery technologies and novel combination drug/device therapies. The drug delivery technologies are based upon a unique and patent-protected principal Bi-Directional Delivery which allows drugs to be more efficiently delivered to the nasal cavity. By applying the Company's drug delivery technology, most of the dose is deposited beyond the nasal valve in the upper posterior two-thirds of the nasal cavity, unlike traditional devices.

The OptiNose delivery devices have high dose reproducibility and avoid drug deposition to the lungs. In summary, the technology fulfills the ideal requirements for nasal drug delivery. Clinical trials have shown the devices can provide a faster onset of action, greater effect with a lower dose and reduced side effects.

Company Growth (employees)
Type
Public
HQ
Oslo, NO
Founded
2000
Size (employees)
44 (est)+5%
OptiNose was founded in 2000 and is headquartered in Oslo, NO

Key People/Management at OptiNose

Peter Miller

Peter Miller

CEO
Ramy Mahmoud

Ramy Mahmoud

President
Per Djupesland

Per Djupesland

CSO

OptiNose Office Locations

OptiNose has offices in Oslo and Berkeley
Oslo, NO (HQ)
Oslo Innovation Center
Berkeley, US
Berkeley House

OptiNose Financials and Metrics

OptiNose Financials

USD

Market capitalization (31-Oct-2017)

761.3 m

Closing share price (31-Oct-2017)

20
OptiNose's current market capitalization is $761.3 m.
Show all financial metrics

OptiNose Market Value History

OptiNose's Web-traffic and Trends

OptiNose Company Life and Culture

You may also be interested in